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ABSTRACT
The long-term outcome of graft failure after allogeneic stem cell transplantation (SCT) has not been well de-
scribed. To fill this knowledge gap we performed a retrospective analysis of patients with graft failure over
a 10-year time period in a single institution. Cases were included for analysis if they had failed to achieve an ab-
solute neutrophil count (ANC) of 500/mL or more by 28 days post-SCT or 42 days after cord blood transplan-
tation (primary graft failure); had a decrease in their ANC to\500/mL for 3 consecutive days after having
achieved neutrophil engraftment (secondary graft failure); or failed to have evidence of at least 5%ormore donor
cell engraftment (primary graft failure with autologous reconstitution). Among 1726 patients who underwent
allografts from January 1, 1990, through December 31, 2000, we identified 68 patients with graft failure. The
1-, 2-, and 5-year overall survival (OS) for all patients was 31%, 24%, and 15%. A diagnosis of acute leukemia
was a significant predictor for poor survival on multivariate analysis. We conclude that graft failure is an uncom-
mon complication postallogeneic SCT, and is associated with poor outcomes. Collection of autologous stem
cells prior to high-risk allografting can salvage a fraction of patients and lead to prolonged survivals.
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Allogeneic hematopoietic stem cell transplantation
(SCT) is being increasingly employed as treatment for
a variety of malignant and nonmalignant hematologic
disorders [1]. Allogeneic SCT is used to rescue patients
from the myeloablative effects of high-dose pretrans-
plant conditioning therapy.Failure to achieve sustained
donor hematopoietic cell engraftment although rare is
a life-threatening complication. Various factors such as
intensity of the preparative regimen, cell dose, cell
manipulation (ie, T cell depletion), prophylaxis used
for prevention of graft-versus-host disease (GVHD),
human leukocyte antigen (HLA) compatibility, toxic-
ities from infections, and administration of drugs that
could damage the allograft have all been identified asinterfering with effective and sustained reconstitution
of hematopoiesis [2,3].
Historically graft failure was a common cause of
treatment failure for patients undergoing allogeneic
transplants for severe aplastic anemia [4,5]. Graft fail-
ure in this setting was thought to result from low cell
doses, relatively low intensity of the conditioning
regimen, and allosensitization of the recipients [5].
Improvements in the conditioning regimen, better
understanding of graft cell dose and composition,
and availability of high-resolution HLA matching
techniques have reduced graft failure rates, but have
not affected recovery from this complication. Treat-
ment strategies of graft failure have generally revolved
around retransplantation and hematopoietic growth859
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comes of these strategies have not been well described
[6-18].
The advent of nonmyeloablative and reduced-
intensity regimens has also changed the transplant
paradigm. In this setting it is possible to have rela-
tively normal hematopoietic function after transplant
without ever having evidence of donor cell engraft-
ment (primary graft failure with autologous recon-
stitution). Thus, graft failure in this situation
would not result in poor hematopoietic function,
but could result in a high rate of disease recurrence
because of the loss of the graft-versus-tumor (GVT)
effect [19].
To determine the long-term outcomes of patients
with graft failure after allogeneic transplantation, as
well as to define prognostic factors for outcomes
and describe the results of different interventions,
we performed a retrospective analysis of patients
with graft failure over a 10-year time period in our in-
stitution. The results of this analysis are described
herein.
PATIENT AND METHODS
A retrospective chart review and waiver of in-
formed consent was approved by the institutional
review board at M.D. Anderson Cancer Center. A da-
tabase review was conducted to identify cases of graft
failure among allograft recipients within the dates of
January 1, 1990, and December 31, 2000. Cases
were included regardless of the underlying diagnosis,
disease status prior to transplant, preparative regimen,
or stem cell source. A patient was considered to have
graft failure if any of these 3 conditions were met: (1)
primary graft failure: failure to achieve an absolute
neutrophil count (ANC) of .500/mL by 28 days after
bone marrow (BM) or peripheral blood progenitor
cell (PB) transplantation or 42 days after cord blood
(CB) transplantation, (2) secondary graft failure: loss
of neutrophil engraftment as determined by an ANC
of \500/mL for 3 consecutive days after having
achieved neutrophil engraftment with documented
donor cell chimerism and no evidence of disease pro-
gression in the marrow, or (3) primary graft failure
with autologous reconstitution defined as achieve-
ment of an ANC of at least 500/mL but without evi-
dence of at least 5% or more donor cell chimerism
as defined by cytogenetics or molecular techniques
[20]. Actuarial survival was estimated by the Kaplan-
Meier methods and compared according to patients’
and transplant characteristics using Cox’s propor-
tional hazards model; P values of .05 or less were con-
sidered statistically significant [21,22]. For the
purpose of this analysis a reduced intense regimen
was defined using the criteria established by Champlin
et al. [19].RESULTS
Incidence and Characteristics of Graft Failure
From a total of 1726 allogeneic transplants per-
formed in our institution between January 1, 1990,
and December 31, 2000, (1008 BM, 681 PB, and 37
CB) a total of 68 patients were identified as having ei-
ther primary or secondary graft failure. Patient charac-
teristics are summarized in Table 1. Twenty-nine
(43%) patients experienced primary graft failure, 30
(44%) secondary graft failure, whereas 9 (13%) had
primary graft failure with autologous reconstitution.
The most common assigned cause of graft failure
was rejection (48%), followed by infection (22%) and
persistent disease (19%). Ten patients received no spe-
cific therapy for graft failure, 19 patients received
growth factors alone (13 of which had secondary graft
failure), and 10 patients had autologous cells infused,
whereas 29 had cells from a donor of which 26 were
procured from the original donor and 3 from a differ-
ent donor. Seventeen patients were reconditioned
prior to reinfusion of donor hematopoietic cells.
Resolution of Graft Failure
Of the 59 patients who developed neutrophil
counts of\500/mL, 38 (64%) had neutrophil recovery
Table 1. Patient Characteristics
Variable
N 68
Median age in years (range) 37 (4-75)
Sex 45 male/23 female
Diagnosis
CML or MPD 22
AML/ALL 17/10
Lymphoma/CLL 13/4
Aplastic anemia 2
Median months from diagnosis
to SCT (range)
31 (2-369)
Donor type
6/6 Related 16
Mismatched related 15
6/6 Unrelated 31
Mismatched unrelated 6
Conditioning regimen
TBI 1 other 37
Other ablative 8
Nonablative or reduced intensity 23
GVHD prophylaxis
Tacrolimus ± other 40
Cyclosporine ± other 20
T cell depletion 8
Stem cell source
Bone marrow 36
Peripheral blood 29
CB 3
N indicates number; CML, chronic myelogenous leukemia; MPD,
myeloproliferative disorder; AML, acute myelogenous leukemia;
ALL, acute lymphoblastic leukemia; GVHD, graft-versus-host
disease; CLL, chronic lymphocytic leukemia; SCT, stem cell
transplant.
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ure diagnosis (range: 8-86 days). Probability of neutro-
phil recovery was higher for patients with secondary
graft failure (70%) than for those with primary graft
failure (59%), but this difference was not statistically
significant. The probability of neutrophil recovery
was similar for patients receiving growth factor ther-
apy compared to those receiving some form of cellular
therapy (67% versus 53%).
Overall Survival
The 1-, 2-, and 5-year overall survival (OS) for all
patients was 31%, 24%, and 15%, respectively. Univar-
iate analysis of patient, disease, and transplant character-
istics associated with survival are summarized in Table
2. A diagnosis of acute leukemia and advanced disease
(acute leukemia either not in remission or beyond sec-
ond remission, accelerated phase chronic myelogenous
leukemia (CML) or chemorefractory lymphoid malig-
nancy) were the only significant predictors of outcome
on univariate analysis with hazard ratios (HRs) of 1.9
Table 2. Patient and Primary Disease Characteristics Associated With
Survival after Graft Failure (Univariate Analysis)
Variable N
N Died at
2 Years
HR at
2 Years 95% CI
P
Value
Age
#37 years 34 24 Ref
.37 years 34 28 1.4 0.8-2.4 0.2
Sex
Male 45 33 Ref
Female 23 19 1.5 0.8-2.6 0.2
Disease risk group
Good 7 3 Ref
Intermediate 10 5 Ref
Advanced 51 44 2.9 1.4-6.2 0.006
Diagnosis
CML/MPD 22 15 Ref
NHL/CLL 17 13 Ref
AA 2 0 Ref
AML/ALL 27 24 1.9 1.1-3.3 0.01
Regimen
TBI 31 24 Ref
Ablative no TBI 14 12 1.2 0.6-2.5 0.5
Reduced intensity 23 16 0.8 0.4-1.4 0.4
Donor type
Matched related 31 25 Ref
Matched unrelated 16 13 Ref
Mismatched related 15 9 0.8 0.7-2.1 0.5
Mismatched unrelated 6 5 0.6 0.2-2.9 0.6
N indicates number; HR, hazard ratios; CI, confidence intervals;
CML, chronic myelogenous leukemia; MPD, myeloproliferative
disorder; AML, acute myelogenous leukemia; ALL, acute lym-
phoblastic leukemia; CLL, chronic lymphocytic leukemia;
SCT, stem cell transplant.
Good Risk: acute leukemia in first remission or CML in first chronic
phase. Intermediate risk: acute leukemia in second remission or
CML in accelerated phase or chemosensitive relapse CLL or
lymphoma.
Advanced disease: acute leukemia in relapse or beyond second remis-
sion or chemorefractory disease.and 2.9, respectively (P values of .02 and .006). Of these
factors, only a diagnosis of acute leukemia remained sig-
nificant on multivariate analysis (HR 5 2.6, P 5 .01).
Outcomes According to Type of Graft Failure
Patients with primary graft failure with autologous
reconstitution had a longer median survival than those
with primary or secondary graft failure (13.7, 2.9, and
3.7 months, respectively, P\ .05). However, 5-year
OS rates were similar for all types of graft failure
with 18%, 11%, and 13% of patients expected to be
alive with primary graft failure, primary graft failure
with autologous reconstitution, and secondary graft
failure, respectively. Most common causes of death
were original malignancy (41%), infection (27%),
and graft failure (18%).
Primary graft failure. Twenty-nine patients had
primary graft failure, attributed to graft rejection in
18 patients, persistent disease in 7 patients, infection
in 3 patients, and an unknown etiology in 1 patient.
Five patients had no specific therapy for graft failure;
1 of those patients eventually engrafted with donor
cells and died 14 months posttransplant from disease
recurrence. The other 4 patients died within 3 months
of initial transplantation either from disease progres-
sion or infectious complications. Seven patients re-
ceived previously cryopreserved, autologous stem
cells as treatment for their graft failure, 6 had autolo-
gous recovery, and 1 died 14 days postinfusion without
signs of neutrophil recovery. Five patients were treated
with growth factors alone and only 1 achieved neutro-
phil recovery with autologous reconstitution, resulting
in a 221 month survival. The other 4 patients died
within 3 months of the original transplant. Five pa-
tients received cells from the original donor without
preceding chemotherapy, 4 of which had neutrophil
recovery with donor cell engraftment. The fifth patient
died from progressive disease without hematologic
recovery. All 5 patients died from either GVHD, infec-
tion, or progressive disease within 8months of original
transplantation (range: 2-8 months).
Seven patients were retransplanted with an alloge-
neic donor; 6 of those received cells from the original
stem cell donor and 1 from an alternate donor. Four
of these had donor cell engraftment, 1 had autologous
reconstitution, and 2 patients died without neutrophil
recovery. Only 2 of these patients survived more than
5 months, 1 died at 20 months from complications of
GVHD, and the patient with autologous reconstitu-
tion remains alive with active CML at the time of
last follow up 721 months posttransplant.
The median survival for patients with primary
graft failure in this analysis was 2.9 months posttrans-
plant (range: 0.8-721months). The outcomes of these
patients according to treatment of graft failure is sum-
marized in Figure 1a.
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Figure 1. (A) Outcomes of primary graft failure according to treatment. (B) Outcomes of secondary graft failure according to treatment failure.
(C) Outcomes of primary graft failure with autologous reconstitution according to treatment failure.Primary graft failure with autologous reconsti-
tution. Nine patients had primary graft failure with
autologous reconstitution; 7 of these were after re-
duced-intensity conditioning (RIC) regimens and 2 af-
ter full-dose conditioning. In 5 patients the cause of
graft failure was ascribed to rejection, whereas in 4 itwas ascribed to persistent disease. Six patients received
subsequent stem cell infusions from the same donor
with (n 5 4) or without (n 5 2) prior chemotherapy.
Two patients received no therapy for graft failure,
while another received growth factors alone. The me-
dian survival of these patients was 13.7 months (range:
Graft Failure Postallogeneic Transplant 8634-931 months). One patient with CML remains alive
in hematologic and cytogenetic remission on imatinib
therapy 931 months postinitial transplant.
Secondary graft failure. Thirty patients had sec-
ondary graft failure, 9 because of rejection, 12 because
of infection, and 9 because of other causes (GVHD,
drugs, and persistent disease). The median time to sec-
ondary graft failure was 51 days (range: 14-356 days).
Thirteen patients received treatment with growth fac-
tor alone. Twelve of these patients had recovery of
graft function, of which 3 were autologous, 8 were
donor derived, and 1 was unknown. Three patients
remain alive at 581, 631, and 741 months.
Five patients received allogeneic stem cells from
the same donor without prior chemotherapy, only 2
of these patients recovered with donor cells, and
none survived for more than a year. Four patients
were retransplanted with the same donor; 2 engrafted
with donor cells, and 1 had autologous reconstitution
only after previously cryopreserved, autologous stem
cells were infused; all of these patients died between
2 and 4 months of initial transplant. Three patients re-
ceived an infusion of their previously cryopreserved
autologous cells; 1 patient had autologous recovery
and died 13 months later from disease progression,
whereas 2 patients died before neutrophil recovery
could occur 2 and 6 days after the autologous stem
cell infusion. Two patients were retransplanted with
an alternate donor; 1 recovered with autologous hema-
topoiesis and is alive 771months postinitial transplant
and the other had donor cell engraftment and died 25
months postinitial transplant from complications of
GVHD. The median survival for all patients with sec-
ondary graft failure was 3.7 months (range: 0.9-771
months).Only 4 patients remain alive at 581, 631,
741, and 771 months postinitial transplant. Out-
comes of patients with secondary graft failure accord-
ing to treatment are summarized in Figure 1b.
Patients with primary graft failure with autologous
reconstitution had a longer median survival than those
with primary or secondary graft failure (13.7, 2.9, and
3.7 months, respectively). However, the 5-year OS
rates were similar for all types of graft failure with
18%, 11%, and 13% of patients expected to be alive
with primary graft failure, primary graft failure with
autologous reconstitution, and secondary graft failure,
respectively. Most common causes of death were graft
failure (18%), infection (27%), or original malignancy
(41%). Kaplan-Meier survival curves according to
graft failure type and treatment are shown in Table 3
and Figure 2A and B.
DISCUSSION
Graft failure has traditionally been viewed as
a complication of allogeneic transplants for aplastic
anemia (AA) patients who had received multiple priortransfusions, or for patients receiving T cell-depleted
transplants [23]. However, with the advent of unre-
lated donor transplantation and particularly before
modern allele typing, alternative donor transplanta-
tion with or without T cell depletion became the
Table 3. Outcomes of Graft Failure According to Treatment
Intervention N Overall Survival at 2 Years
None 10 22%
Growth Factors 19 21%
Autologous infusion 10 50% P 5 .08
Allogeneic backup infusion 12 8%
Retransplant same donor 14 14%
Retransplant different donor 3
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Figure 2. (A,B)OS according to treatment of graft failure and type of
graft failure.
864 G. Rondon et al.most common situation associated with graft failure,
occurring in up to 14% of patients in the initial Na-
tional Marrow Donor Program experience [24].
Improved tissue typing techniques as well as im-
provements in conditioning and patient selection
have reduced the risk of graft failure, but this still rep-
resents an important complication of allografting
particularly after alternative donor transplantation
[24]. The optimal therapy for patients who develop
graft failure has not been defined, and a variety of ap-
proaches from growth factors to retransplantation
have been proposed [6-18]. To develop a rationale ap-
proach for the management of this potentially life-
threatening complicationwe performed a retrospective
review of treatment outcomes among 68 patients who
developed this complication during a 10-year period in
our institution. This retrospective analysis confirmed
that graft failure is a relatively rare complication
(only 68 cases among 1726 transplants). Notwith-
standing, graft failure was still associated with poor
outcomes despite successful recovery of hematologic
function.
Of particular interest in this retrospective review
was the natural history of patients developing graft
failure after RIC or truly nonablative regimens. It
was initially thought that these patients would have au-
tologous reconstitution if donor cell engraftment did
not occur [25]. Twenty-three of the 68 patients with
graft failure in this analysis had been conditioned
with either an RIC (n 5 7) or a truly nonablative reg-
imen (n5 16). Of these, 7 died without ever having re-
covered hematologic function between 0 and 173 days
postdiagnosis of graft failure. These results underscore
that in patients undergoing RIC who fail to engraft or
lose graft function, aggressive treatment of graft failure
should be implemented, because autologous reconsti-
tution is far from certain.
Seven of the 8 patients surviving 5 years or more
had autologous hematopoietic recovery, 3 of them be-
cause of infusion of previously cryopreserved autolo-
gous stem cells. This observation confirms the report
by Mehta et al. [9], and underscores the importance
of autologous stem cell cryopreservation for patients
at high risk for graft failure because of stem cell source
or graft manipulation (ie, alternative donor transplants
or T cell depletion). Five of these patients were still
alive at last follow-up (631, 711, 721, 771, and
931 months after initial transplant). Three of these
patients had CML, 1 had AA, and interestingly, 1 pa-
tient with refractory acute myelogenous leukemia
(AML) remains alive with normal hematologic param-
eters despite autologous reconstitution with signifi-
cant cytogenetic abnormalities 741 months after
initial transplant. This long-term remission of a patient
with a refractory hematologic malignancy despite ab-
sence of detectable donor cells has been observed by
other investigators and suggests that a GVT effectmay be operative at levels below our current limit of
detection of donor cells [26,27].
This 10-year experience suggests that an aggres-
sive approach to patients with graft failure will be
needed to improve outcomes. This begins by identify-
ing patients at high risk for this complication and
developing strategies for early intervention. This ret-
rospective experience supports the recommendation
that patients with indolent diseases and patients with
acute leukemia in remission should have autologous
stem cells cryopreserved if they are to undergo an allo-
geneic transplant with an alternative source of stem
cells (ie, mismatched or CB transplants) or cells that
are to be manipulated. Seven of the 10 patients who re-
ceived cryopreserved autologous stem cells for treat-
ment of graft failure had neutrophil recovery and had
a median survival of 21 months. Because of the retro-
spective nature of this review, we were unable to deter-
mine why certain patients received certain therapies
for graft failure (ie, infusion of cells with or without
preceding chemotherapy, use of alternate donor, etc).
In this regard, various reports have appeared demon-
strating that immunosuppressive conditioning is effec-
tive in securing donor cell engraftment in the setting of
graft failure with good tolerance and efficacy [13-17].
During the initial years of this analysis no interven-
tion was planned until after day 28 when a BM aspirate
confirmed lack of donor cell engraftment. We now
recommend intervening as soon as it seems likely
that delayed hematologic recovery or graft failure
may occur (usually 3 weeks after transplant). Initial in-
terventions include: (1) reassessment of all ongoing
medications to eliminate all nonessential potentially
stem cell toxic drugs (ie, linezolid, acyclovir, ganciclo-
vir, and so forth), (2) early assessment of BM aspiration
looking for persistent disease or viral infections (ie,
HHV6, parvovirus, CMV, and so forth), (3) institution
of intensive growth factor therapy if this has not begun
already, and (4) establishing a definitive plan if hema-
tologic recovery has not been achieved by 28 days post-
transplant (ie, infusing cryopreserved autologous stem
cells, contacting the original stem cell donor or an al-
ternative donor to procure additional stem cells, as-
sessment for investigational strategies, etc.) [6-18,29].
The issue of early identification and intervention has
also been addressed by Mehta et al., who have recom-
mended considering interventions in patients who
have not achieved a peripheral blood leukocyte count
of .200/mL by day 16 post-SCT [28]. Retransplanta-
tion using novel immunosuppressive regimens can
be successful in achieving donor cell engraftment
and can be associated with long-term disease control
[6-10,12-18].
CB transplantation is being used increasingly in
adults, and is associated with a higher risk of graft failure
than BM or peripheral blood SCT. Chan et al. [15] re-
cently reviewed their experience with graft failure after
Graft Failure Postallogeneic Transplant 865CB transplantation. Seventy-one of 110 pediatric pa-
tients had achieved a neutrophil count of 400/mL or
greater by day 28, of the remaining 33 patients who
were still neutropenic, 20 eventually attained donor my-
eloid recovery and 10 survived without donor-derived
hematopoiesis. These patients received a second umbili-
cal CB transplant with 9 patients engrafting. Six of these
patients remainedaliveat the timeof thereportwithame-
dian survival of over 2 years. Thus, waiting until day 42
post-CB transplant before interveningmaybe reasonable
for the stable patient with autologous stem cells cryopre-
served, but may not be appropriate for other patients.
In conclusion, graft failure is a rare complication
postallogeneic SCT, but is associated with poor out-
comes. Collection of autologous stem cells prior to
high-risk allografting, as well as aggressive interven-
tions can salvage a fraction of patients and lead to pro-
longed survivals. Disease recurrence after resolution of
graft failure remains an important cause of treatment
failure, suggesting that once the patient is stabilized se-
rious consideration to definitive therapy should once
again be considered.
REFERENCES
1. Armitage J. Bone marrow transplantation. N Engl J Med. 1994;
330:827-838.
2. Tabbara I, Zimmermann K, Morgan C, Nahleh Z. Allogeneic
hematopoietic cell transplantation; complications and results.
Arch Intern Med. 2002;162:1558-1562.
3. Thomas ED, Fefer A, Buckner CD, Storb R. Current status of
bone marrow transplantation for aplastic anemia and acute leu-
kemia. Blood. 1977;49:671-681.
4. Storb R. Graft rejection and graft versus host disease in marrow
transplantation. Transplant Proc. 1989;23(1 Pt 3):2915-2918.
5. Storb R, Thomas ED, Buckner CD, et al. Marrow transplanta-
tion for aplastic anemia. Semin Hematol. 1984;21:27-35.
6. Weisdorf D, Verfaillie CM, Davies SM, et al. Hematopoietic
growth factors for graft failure after bone marrow transplanta-
tion: a randomized trial of granulocyte macrophage colony-
stimulating factor (GM-CSF) versus sequential GM-CSF plus
granulocyte-CSF. Blood. 1995;85:3452-3456.
7. Davies SM, Weisdorf DJ, Haake RJ, et al. Second infusion of
bone marrow for treatment of graft failure after allogeneic
bone marrow transplantation. Bone Marrow Transplant. 1994;4:
73-77.
8. Remberger M, Ringden O, Ljungman P, et al. Booster marrow
or blood cells for graft failure after allogeneic bone marrow
transplantation. Bone Marrow Transplant. 1998;22:73-78.
9. Mehta J, Powles R, Singhal S, et al. Outcome of autologous res-
cue after failed engraftment of allogeneic marrow. Bone Marrow
Transplant. 1996;17:213-217.
10. Woodard P, Tong X, Richardson S, et al. Etiology and outcome
of graft failure in pediatric hematopoietic stem cell transplant re-
cipients. J Pediatr Hematol Oncol. 2003;25:955-959.
11. Nemunaitis J, Singer JW,BucknerCD, et al.Use of recombinant
granulocyte-macrophage colony-stimulating factor in graft fail-
ure after bone marrow transplantation. Blood. 1990;76:245-253.
12. Grandage VL, Cornish JM, Pamphilon DH, et al. Second allo-
geneic bone marrow transplants from unrelated donors for graftfailure following initial unrelated bone marrow transplantation.
Bone Marrow Transplant. 1998;21:687-690.
13. Guardiola P, KuentzM, Garban F, et al. Second early allogeneic
stem cell transplantations for graft failure in acute leukemia,
chronic myeloid leukaemia and aplastic anemia. French Society
of Bone Marrow Transplantation. Br J Haematol. 2000;111:
292-302.
14. Jabbour E, Rondon G, Anderlini P, et al. Treatment of donor
graft failure with nonmyeloablative conditioning of fludarabine,
antithymocyte globulin and a second allogeneic hematopoietic
transplantation. Bone Marrow Transplant. 2007;40:431-435.
15. Chan KW, Grimley MS, Taylor C, Wall DA. Early identifica-
tion and management of graft failure after unrelated CB trans-
plantation. Bone Marrow Transplant. 2008;10:1-7.
16. Heinzelmann F, Lang PJ, Ottinger H, et al. Immunosuppressive
total lymphoid irradiation-based reconditioning regimens en-
able engraftment after graft rejection or graft failure in patients
treated with allogeneic hematopoietic stem cell transplantation.
Int J Radiat Oncol Biol Phys. 2008;70:523-528.
17. Lang P, Mueller I, Greil J, et al. Retransplantation with
stem cells from mismatched related donors after graft re-
jection in pediatric patients. Blood Cells Mol Dis. 2008;40:
33-39.
18. Chen J, Law P, Ball E. Failure of engraftment. In: Ball E,
Lister J, Law P, editors. Hematopoietic Stem Cell Therapy, 1st
ed. Philadelphia: Churchill-Livingston; 2000. p. 521-531.
19. Champlin R, Khouri I, Kornblau S, Molldrem, Giralt S. Rein-
venting bone marrow transplantation. Nonmyeloablative pre-
parative regimens and induction of graft-vs-malignancy effect.
Oncology. 1999;13:621-628.
20. Antin JH, Childs R, Filipovich AH, et al. Establishment of com-
plete and mixed donor chimerism after allogeneic lymphohema-
topoietic transplantation: recommendations from a workshop at
the 2001 Tandem Meetings of the International Bone Marrow
Transplant Registry and the American Society of Blood and
Marrow Transplantation. Biol Blood Marrow Transplant. 2001;
7:473-485.
21. Kaplan EL,Meier P. Nonparametric estimator from incomplete
observations. J Am Stat Assoc. 1958;53:457-481.
22. Cox DR. Regressionmodels and life tables (with discussion). J R
Stat Soc B. 1972;34:187.
23. Storb R, Prentice RL, Thomas ED, et al. Factors associated with
graft rejection after HLA identical marrow transplantation for
aplastic anemia. Br J Haematol. 1983;55:573-585.
24. Kernan NA, Bartsch G, Ash RC, et al. Retrospective analysis of
462 unrelated marrow transplants facilitated by the National
MarrowDonor Program (NMDP) for the treatment of acquired
and congenital disorders of the lymphohematopoietic system
and congenital metabolic disorders. N Engl J Med. 1993;328:
593-602.
25. Baron F, Baker JE, Storb R, et al. Kinetics of engraftment in
patients with hematologic malignancies given allogeneic hema-
topoietic cell transplantation after non myeloablative condition-
ing. Blood. 2004;104:2254-2262.
26. Ballen KK, ColvinG, Porter D, Quesenberry PJ. Low dose total
body irradiation followed by allogeneic lymphocyte infusion for
refractory hematologic malignancy—an updated review. Leuke-
mia Lymphoma. 2004;45:905-910.
27. Ballen KK, Becker PS, Emmons RV, et al. Low-dose total body
irradiation followed by allogeneic lymphocyte infusion may in-
duce remission in patients with refractory hematologic malig-
nancy. Blood. 2002;100:442-450.
866 G. Rondon et al.28. Hachem RY, Hicks K, Huen A, Raad I. Myelosuppression and
serotonin syndrome associated with concurrent use of linezolid
and selective serotonin reuptake inhibitors in bone marrow
transplant recipients. Clin Infect Dis. 2003;37:e8-e11.29. Mehta J, Powles R, Singhal S, et al. Early identification of patients
at risk of death because of infections, hemorrhage, or graft failure
after allogeneic bone marrow transplantation on the basis of the
leukocyte count. Bone Marrow Transplant. 1997;19:349-355.
